Introduction. ER, PR, and HER2 are routinely available in breast cancer specimens. The
purpose of this study is to contrast breast cancer‐specific survival for the eight ER/PR/HER2 …

Breast cancer research examining either molecular profiles or biomarker subtypes has
focused on the estrogen receptor negative/progesterone receptor negative/human …

Purpose The purpose of this study was to assess differences in breast cancer-specific
mortality within tumors of the same size when breast cancer was defined using the three …

Objective: To compare the clinicopathologic features and survival in the four breast cancer
subtypes defined by immunohistochemistry (IHC) expression of estrogen receptor (ER) or …

Abstract Background The 2007 St Gallen international expert consensus statement
describes three risk categories and provides recommendations for treatment of early breast …

BACKGROUND: Both age and race have been identified as independent predictors of
breast cancer subtype but the association of age with subtype within each race is not well …

Estrogen receptor (ER), progesterone receptor (PR), and epidermal growth factor receptor 2
(HER 2) status are well‐established prognostic markers in breast cancer management. The …

Background: Although incidence rates of breast cancer molecular subtypes are well
documented, effects of molecular subtypes on breast cancer–specific survival using the …

Various subtypes of breast cancer defined by estrogen receptor (ER), progesterone receptor
(PR), and HER2 exhibit etiologic differences in reproductive factors, but associations with …

Background In breast cancer, immunohistochemistry (IHC) subtypes, together with grade
and stage, are well-known independent predictors of breast cancer death. Given the …